ADMA Biologics, Inc.’s (ADMA) shares have surged 31.4% in a month compared with the industry’s growth of 1.4%. The stock hit its 52-week high of $17.87 on Aug 14.The significant growth can be attributed to the company’s better-than-expected second-quarter results, wherein both the top and bottom-lines beat their estimates. The company also raised its annual guidance for 2024 and 2025 revenues and net income, based on the continuous growth of its unique and proprietary immunoglobulin, Asceniv.ADMA expects to ...